Trials / Completed
CompletedNCT02098291
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G17DT |
Timeline
- Start date
- 1999-04-01
- Primary completion
- 2001-07-01
- Completion
- 2002-02-01
- First posted
- 2014-03-28
- Last updated
- 2014-03-28
Source: ClinicalTrials.gov record NCT02098291. Inclusion in this directory is not an endorsement.